<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR12">
 <label>12.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jain</surname>
    <given-names>MK</given-names>
   </name>
   <name>
    <surname>Thamer</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Therapondos</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Shiffman</surname>
    <given-names>ML</given-names>
   </name>
   <name>
    <surname>Kshirsagar</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Clark</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <article-title>Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?</article-title>
  <source>Hepatology</source>
  <year>2019</year>
  <volume>69</volume>
  <fpage>51</fpage>
  <lpage>63</lpage>
  <pub-id pub-id-type="doi">10.1002/hep.30171</pub-id>
  <pub-id pub-id-type="pmid">30019478</pub-id>
 </element-citation>
</ref>
